v3.26.1
Shareholders' Equity
 6 Months Ended
Jun. 30, 2026
Shareholders’ Equity [Abstract]  
SHAREHOLDERS’ EQUITY

NOTE 5 – SHAREHOLDERS’ EQUITY

 

Share-based expenses recognized in the financial statements:

 

    For the
three months
ended
June 30,		     For the
three months
ended
June 30,		     For the
six months
ended
June 30,		     For the
six months
ended
June 30,		  
    2026     2025     2026     2025  
    Unaudited  
                         
Research and development expenses     -       11       -       103  
General and administrative expenses     111       143       111       391  
                                 
Total     111       154       111       494  

 

    Unaudited  
    Number of
options		     Weighted
average
exercise
price		     Weighted
average
remaining
contractual
terms
(in years)		     Aggregate
intrinsic
value		  
                         
Outstanding as of January 1, 2026     4,270,000       0.30       4.90       -  
Exercised     (740,000 )     0.30       -       -  
                                 
Outstanding at June 30, 2026     3,530,000       0.30       2.67       -  
                                 
Vested and expected to vest at June 30, 2026     3,530,000       0.30       2.67       -  
                                 
Exercisable as of June 30, 2026     3,530,000       0.30       2.67       -  

 

On March 4, 2026, a former employee of the Company exercised 740,000 options on a cashless basis into 592,000 shares of common stock of the Company. As of the balance sheet date, the shares had not yet been issued.